PURPOSE: The purpose of this study was to compare Functional Assessment of Cancer Therapy-Esophagus (FACT-E) questionnaire changes during proton (PRT) or photon (XRT) chemoradiation therapy (CRT) for esophageal cancer (EC). METHODS AND MATERIALS: We reviewed patients enrolled in a prospective registry who received preoperative or definitive CRT for EC. Patients completed the FACT-E before CRT and during the last week of CRT. Analysis of variance testing was used to assess associations between patient and treatment characteristics and FACT-E score changes. RESULTS: One hundred twenty-five patients completed a baseline and posttreatment FACT-E; 63 received XRT and 62 received PRT. The mean age was 65 years; the PRT group was older (68 vs 64 years, P = .0063). The following characteristics were similar between cohorts: 83% male, 78% adenocarcinoma, and 89% stage II-III. The radiation therapy prescription dose was higher in the PRT group (≥50 Gy in 94% vs 67%, P < .0001), whereas the median clinical target volume was smaller in the PRT group (553 vs 668 cm3, P = .013). Most (96%) received concurrent weekly carboplatin-paclitaxel. The mean FACT-E score was 136.3 (standard deviation [SD] 21.0) at baseline and 119.6 (SD 24.8) post-CRT, with mean change of -16.7 (SD 19.8). Baseline scores were comparable between XRT and PRT groups (135.9 vs 136.7, P = .82). On univariate and multivariate analyses, less mean decline in FACT-E score was observed for PRT versus XRT (-12.7 vs -20.6, P = .026) and for trimodality versus definitive therapy (-13.0 vs -22.5, P = .008). CONCLUSIONS: For patients receiving CRT for EC, PRT was associated with less decline in FACT-E scores compared with XRT.
PURPOSE: The purpose of this study was to compare Functional Assessment of Cancer Therapy-Esophagus (FACT-E) questionnaire changes during proton (PRT) or photon (XRT) chemoradiation therapy (CRT) for esophageal cancer (EC). METHODS AND MATERIALS: We reviewed patients enrolled in a prospective registry who received preoperative or definitive CRT for EC. Patients completed the FACT-E before CRT and during the last week of CRT. Analysis of variance testing was used to assess associations between patient and treatment characteristics and FACT-E score changes. RESULTS: One hundred twenty-five patients completed a baseline and posttreatment FACT-E; 63 received XRT and 62 received PRT. The mean age was 65 years; the PRT group was older (68 vs 64 years, P = .0063). The following characteristics were similar between cohorts: 83% male, 78% adenocarcinoma, and 89% stage II-III. The radiation therapy prescription dose was higher in the PRT group (≥50 Gy in 94% vs 67%, P < .0001), whereas the median clinical target volume was smaller in the PRT group (553 vs 668 cm3, P = .013). Most (96%) received concurrent weekly carboplatin-paclitaxel. The mean FACT-E score was 136.3 (standard deviation [SD] 21.0) at baseline and 119.6 (SD 24.8) post-CRT, with mean change of -16.7 (SD 19.8). Baseline scores were comparable between XRT and PRT groups (135.9 vs 136.7, P = .82). On univariate and multivariate analyses, less mean decline in FACT-E score was observed for PRT versus XRT (-12.7 vs -20.6, P = .026) and for trimodality versus definitive therapy (-13.0 vs -22.5, P = .008). CONCLUSIONS: For patients receiving CRT for EC, PRT was associated with less decline in FACT-E scores compared with XRT.
Authors: Jana M Kobeissi; Charles B Simone; Lara Hilal; Abraham J Wu; Haibo Lin; Christopher H Crane; Carla Hajj Journal: Cancers (Basel) Date: 2022-06-10 Impact factor: 6.575
Authors: Ronik S Bhangoo; Todd A DeWees; Nathan Y Yu; Julia X Ding; Chenbin Liu; Michael A Golafshar; William G Rule; Sujay A Vora; Helen J Ross; Daniel H Ahn; Staci E Beamer; Dawn E Jaroszewski; Christopher L Hallemeier; Wei Liu; Jonathan B Ashman; Terence T Sio Journal: Adv Radiat Oncol Date: 2020-05-19
Authors: Kimberly R Gergelis; Krishan R Jethwa; Erik J Tryggestad; Jonathan B Ashman; Michael G Haddock; Christopher L Hallemeier Journal: J Thorac Dis Date: 2020-11 Impact factor: 2.895
Authors: Michael D Chuong; Christopher L Hallemeier; Heng Li; Xiaorong Ronald Zhu; Xiaodong Zhang; Erik J Tryggestad; Jen Yu; Ming Yang; J Isabelle Choi; Minglei Kang; Wei Liu; Antje Knopf; Arturs Meijers; Jason K Molitoris; Smith Apisarnthanarax; Huan Giap; Bradford S Hoppe; Percy Lee; Joe Y Chang; Charles B Simone; Steven H Lin Journal: Front Oncol Date: 2021-10-19 Impact factor: 6.244
Authors: Steven H Lin; Kaiping Liao; Xiudong Lei; Vivek Verma; Sherif Shaaban; Percy Lee; Aileen B Chen; Albert C Koong; Wayne L Hoftstetter; Steven J Frank; Zhongxing Liao; Ya-Chen Tina Shih; Sharon H Giordano; Grace L Smith Journal: Int J Part Ther Date: 2022-06-23